A recent meta-analysis by Canonica et al71 assessed the efficacy of desloratadine in the treatment of symp- toms of AR in randomized clinical trials. In 5 allergen challenge studies and trials conducted in a clinical set- ting that included objectively measured nasal obstruc- tion as an end point (N = 438), nasal airflow was significantly improved with desloratadine compared with placebo (standardized mean difference: 0.32; 95% CI, 0.10–0.55; P = 0.005).